Abbott/Sandoz’ Hytrin Agreement Violates Antitrust Law, Judge Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A provision under which Sandoz (formerly Geneva) agreed not to market generic terazosin until an appellate ruling in underlying patent litigation “exceeded the scope” of the potential exclusionary effect of Abbott’s patent, court says. The ruling marks the second time the judge has found the agreement to violate antitrust law.
You may also be interested in...
Supreme Court Declines To Hear Cardizem CD, Hytrin Antitrust Cases
The two cases created an apparent disagreement among the federal appellate circuits on the legality of “reverse payments” from a brand company to delay a generic’s entry.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.
ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages
ADHD drug shortages may have resulted from industry reticence to fill DEA quotas, as well as a 'heavy element of professional responsibility' with off-label prescribing, Robert Califf told a House appropriations subcommittee.